アブストラクト
| Title | NSAIDs不耐症 / アスピリン喘息 (AERD) における病態解明の進歩と臨床的側面 |
|---|---|
| Subtitle | 総合医学会報告 シンポジウム : 「アレルギー・リウマチ領域における最先端の臨床研究」【アレルギー領域】 |
| Authors | 谷口正実† |
| Authors (kana) | |
| Organization | 国立病院機構相模原病院 臨床研究センター (現所属: 湘南鎌倉総合病院免疫・アレルギーセンター) †医師 |
| Journal | 医療 |
| Volume | 74 |
| Number | 10 |
| Page | 428-436 |
| Year/Month | 2020 / 10 |
| Article | 報告 |
| Publisher | 国立医療学会 |
| Abstract | 「要旨」 ・NSAIDs過敏症は, 非免疫学機序のNSAIDs不耐症と単一のNSAIDに対するアレルギーなどに分類される. ・不耐症は気道(喘息+鼻茸)型と皮膚(蕁麻疹/血管浮腫)型があり, ともに臨床現場でよく経験される. 一方, NSAIDアレルギーは, 連用による感作で生じるまれな病態である. ・気道型不耐症は, アスピリン喘息(AERD)と称され, 成人喘息の5-10%を占め, 重症喘息の中で最も重要かつ高頻度である. ・AERDは, 好酸球性鼻副鼻腔炎, NSAIDs過敏, システィニルロイコトリエン過剰産生を特徴とするが, いまだ発症原因は不明である. ・通常のアレルギー検査では同定できず, 診断のゴールドスタンダードは, アスピリン内服試験である. ・COX-1阻害作用を有するすべてのNSAIDs(貼付薬などあらゆる剤型を含む)で重篤な気道狭窄を生じやすいため, それらは禁忌である. 一方, COX-1阻害作用がほとんどないセレコキシブやアセトアミノフェンは安全に使用できる. ・AERDの病態解明や治療において, 国立病院機構相模原病院臨床研究センターは多くの世界的な業績をあげた. |
| Practice | 医学総合 |
| Keywords | アスピリン喘息 (AERD), NSAIDs不耐症, aspirin-exacerbated respiratory disease, NSAIDs intolerance |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 谷口正実. 喘息の亜型・特殊型・併存症 アスピリン喘息(NSAIDs過敏喘息). 日内会誌 2013;102:1426-32.
- 2) Szczeklik A, Stevenson DD. Aspirin-induced asthma:advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913-21.
- 3) Taniguchi M, Mitsui C, Hayashi H et al. Aspirin-exacerbated respiratory disease(AERD):Current understanding of AERD. Allergol Int 2019;68:289-95.
- 4) Kowalski ML, Agache I, Bavbek S et al. Diagnosis and management of NSAID-exacerbated respiratory disease(N-ERD)-a EAACI position paper. Allergy 2019;74:28-39.
- 5) Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. J Allergy Clin Immunol Pract 2017;5:537-45.
残りの31件を表示する
- 6) 福冨友馬, 谷口正実, 粒来崇博ほか. 本邦における病院通院成人喘息患者の実態調査 国立病院機構ネットワーク共同研究. アレルギー 2010;59:37-46.
- 7) Morales DR, Guthrie B, Lipworth BJ et al. NSAID-exacerbated respiratory disease:a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy 2015;70:828-35.
- 8) Fukutomi Y, Taniguchi M, Watanabe J et al.. Time trend in the prevalence of adult asthma in Japan:findings from population-based surveys in Fujieda City in 1985,1999, and 2006. Allergol Int 2011;60:443-8.
- 9) Sekiya K, Nakatani E, Fukutomi Y et al. Severe or life-threatening asthma exacerbation:patient heterogeneity identified by cluster analysis. Clin Exp Allergy 2016;46:1043-55.
- 10) Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16:432-6.
- 11) Mascia K, Haselkorn T, Deniz YM et al. Aspirin sensitivity and severity of asthma:evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005;116:970-5.
- 12) Fukutomi Y, Taniguchi M, Tsuburai T et al. Obesity and aspirin intolerance are risk factors for difficult-to-treat asthma in Japanese non-atopic women. Clin Exp Allergy 2012;42:738-46.
- 13) Schatz M, Hsu JW, Zeiger RS et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol 2014;133:1549-56.
- 14) Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-13.
- 15) Shah NH, Schneider TR, DeFaria Yeh D et al. Eosinophilia-Associated coronary artery vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2016;4:1215-9.
- 16) Virchow C, Szczeklik A, Bianco S et al. Intolerance to tartrazine in aspirin-induced asthma:results of a multicenter study. Respiration 1988;53:20-3.
- 17) Hayashi H, Fukutomi Y, Mitsui C et al. Smoking Cessation as a Possible Risk Factor for the Development of Aspirin-Exacerbated Respiratory Disease in Smokers. J Allergy Clin Immunol Pract 2018;6:116-25.e3.
- 18) Kawagishi Y, Mita H, Taniguchi M et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002;109:936-42.
- 19) Higashi N, Taniguchi M, Mita H et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleuko-trienuria):Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004;113:277-83.
- 20) Higashi N, Taniguchi M, Mita H et al. Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E (4 LTE 4) and prostaglandin D (2 PGD 2) metabolites. Allergol Int 2012;61:393-403.
- 21) Mita H, Endoh S, Kudoh M et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001;56:1061-7.
- 22) Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010;125:1084-91.
- 23) Higashi N, Mita H, Yamaguchi H et al. Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis. J Allergy Clin Immunol 2012;129:557-9, 559.e1-2.
- 24) Yamaguchi H, Higashi N, Mita H et al. Urinary concentrations of 15-epimer of lipoxin A (4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin Exp Allergy 2011;41:1711-8.
- 25) Ono E, Taniguchi M, Higashi N et al. Increase in salivary cysteinyl-leukotriene concentration in patients with aspirin-intolerant asthma. Allergol Int 2011;60(1):37-43.
- 26) Mitsui C, Kajiwara K, Hayashi H et al. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2016;137:400-11.
- 27) Hayashi H, Mitsui C, Nakatani E et al. Omalizumab reduces cysteinyl leukotriene and 9α, 11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2016;137:1585-7.e4.
- 28) White AA, Doherty TA. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis. Am J Rhinol Allergy 2018;32:7-11.
- 29) 谷口正実. アレルギー実践講座 気道過敏性検査とアスピリン負荷試験の実際. アレルギー 2009;58:87-96.
- 30) Settipane RA, Schrank PJ, Simon RA et al. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:480-5.
- 31) 谷口正実. 私の治療 アスピリン喘息における点滴静注ステロイド薬の使い方. アレルギーの臨 2003;23:741-3.
- 32) 妹川史朗, 佐藤篤彦, 谷口正実ほか. クロモグリク酸ナトリウムは発作寛解期のアスピリン喘息患者に対して急性気管支拡張効果を有する. アレルギー 1992;41:1515-20.
- 34) Laidlaw TM, Mullol J, Fan C et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract 2019;7:2462-5.e1.
- 35) Buchheit KM, Cahill KN, Katz HR et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2016;137:1566-76.e5.
- 36) White AA, Stevenson DD. Aspirin-Exacerbated Respiratory Disease. N Engl J Med 2018;379:1060-70.
- 37) Adelman J, McLean C, Shaigany K et al. The Role of Surgery in Management of Samter's Triad:A Systematic Review. Otolaryngol Head Neck Surg 2016;155:220-37.
